fail primari endpoint lower price
reiter market outperform rate lower price target
previous incyt corpor base discount earn
per share revenu multipl analysi yesterday announc
phase trial itacitinib plu corticosteroid patient
steroid-nav acut graft-versus-host diseas sn-agvhd fail meet
primari endpoint improv overal respons rate orr day compar
placebo plu corticosteroid although itacitinib still test sn-
chronic gvhd phase trial remov itacitinib
sn-agvhd sn-cgvhd model result decreas
price target despit belief itacitinib like commerci
continu recommend share sinc ruxolitinib rux remain well
posit gener sale expect stock trade
approxim lower would buyer weak base value-
creat mileston pemigatinib may pdufa data novarti
nv nc begin world-wid file sr-agvhd phase trial evalu
rux multipl dermatolog indic pois report result well
cash posit pro forma
itacitinib perform expect placebo arm perform better
expect confer call manag note
orr itacitinib plu corticosteroid arm line prior phase ii
data howev analysi suggest result came lower
previous report failur achiev
statist signific improv placebo plu corticosteroid arm
 also due higher-than-expect orr control arm
vs expect data analyz come
week top-lin result suggest us current assumpt util
on-going itacitinib studi may need reevalu manag
went great length indic result necessarili read
itacitinib sn-cgvhd phase trial
gvhd prophylaxi exploratori phase trial believ
conserv stanc taken investor
itacitinib model failur
lower probabl success po itacitinib sn-
agvhd base bull case even though differ
agvhd cgvhd result inspir confid
prospect concern placebo arm could
similarli outperform expect consequ lower po
itacitinib sn-cgvhd base bull case
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
lower price target high expect rux drive bullish outlook
remov itacitinib model estim revenu decreas
believ remain under-valued base primarili
strength rux franchis specif see potenti continu growth
polycythemia vera pv market could see increas revenu
well steroid-refractori agvhd figur
figur revenu growth expect product indic
product revenu million revenu product revenu million revenu increas jakavi royalti mf royalti dilut ruxolitinib revenu split mf pv known includ potenti off-label use rux incyt corpor
valu biotechnolog compani base blend discount earn per share revenu
multipl analysi first evalu univers profit biotechnolog compani deriv
revenu multipl rang ep multipl rang base compani trade bear
bull market end ascertain rang revenu multipl
earn per share multipl
appli price-to-earnings multipl probability-adjust earn per share approxim
discount period obtain fair valu per share appli
revenu multipl probability-adjust revenu discount
period obtain per share fair valu averag result two method
ad anticip ye cash per share million share deriv
price target round
figur blend discount earn per share revenu multipl analysi
estim revenu combin increas sale exist
commerci product ruxolitinib mf pv sr-agvhd ponatinib cml baricitinib
ra potenti sale product believ high likelihood approv
pemigatinib cholangiocarcinoma ruxolitinib sr-cgvhd
base scenario includ potenti revenu rux cream sale mild
moder ad vitiligo pemigatinib sale bladder cancer itacitinib sn-cgvhd
bull scenario adjust probabl success program base
confid data seen far includ risk-adjust revenu key pipelin product
valuat figur result fair valu
bear scenario remov risk-adjust revenu itacitinib assum lower-than-
expect long-term jakafi sale base scenario fair valu
figur chart incyt close price previou month price project
compani could achiev month bull base bear case scenario
bullbasebearrux cream ad cream ad cream vitiligo cream vitiligo sr-cgvhd sr-agvhd sr-cgvhd cholangio uretheli cancer cholangio uretheli cancer sn-agvhd sn-cgvhd sn-agvhd sn-cgvhd revenu mm dilut non-gaap ep success incyt corpor
revenu lower longer includ itacitinib sale sn-agvhd sn-cgvhd
expens decreas reflect lower revenu base
incyt corpor incom statementfigur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad -- -- -- -- pemigatinib cholangio uc -- total product revenu product royalti contract revenue- mileston total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss unreal gain loss long term interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor figur incom statement annual
incyt corpor incom statementfigur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad pemigatinib cholangio uc total product revenu product royalti contract revenue- mileston total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss unreal gain loss long term interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor incyt corpor
wilmington delaware-bas incyt corpor drug discoveri develop compani grow pipelin novel small-molecul
drug treat variou inflammatori disord cancer
risk invest thesi valuat includ clinic develop competit regulatori sector
clinic develop risk drug develop riski capital-intens endeavor major drug enter clinic develop
fail reach market
competit risk drug market develop condit program address lack
differenti clinic data drug and/or approv competit drug may advers impact sale potenti product
regulatori risk like drug develop compani reliant upon fda pace evalu new drug agenc
willing approv new drug
sector risk valuat biotechnolog stock subject investor assess prospect underli compani investor
toler risk confid prospect biotechnolog stock group therefor stock price may fall even
compani meet exce investor expect
